Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC68498 in Advanced Refractory Solid Tumors
NCT04324372Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HEC68498 in solid tumor (advanced stage), breast cancer, colorectal cancer (CRC) and 1 more, sponsored by Sunshine Lake Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2019; status: completed.
02
Drugs
HEC68498
03
Conditions
solid tumor (advanced stage)breast cancercolorectal cancer (CRC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04324372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324372.